Blood markers for the selection of adjuvant chemotherapy and the method using thereof

The present invention relates to a marker for the selection of standard anticancer chemotherapy affecting the postoperative prognosis in patients with gastric cancer. More specifically, the present invention includes a combination of complement component C5 (CO5), complement component C9 (CO9) and p...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	AHN HEE SUNG, JU SHINYEONG, LEE CHEOLJU, SHIN SUNGHO, KIM SEUNG TAE, KWON YU MI, LEE SEONJEONG, LEE JEE YUN, PRASHANT KAUSHAL, SOHN TAE SUNG, KIM SU MI
Format:	Patent
Sprache:	eng ; kor
Schlagworte:	INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING PHYSICS TESTING
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to a marker for the selection of standard anticancer chemotherapy affecting the postoperative prognosis in patients with gastric cancer. More specifically, the present invention includes a combination of complement component C5 (CO5), complement component C9 (CO9) and prothrombin (F2), and measures the expression level of the CO5, C09 and F2 in blood, serum or plasma of gastric cancer patients, thereby providing a marker for gastric cancer prognosis that can determine the prognosis of gastric cancer. 본 발명은 위암 환자의 수술 후 예후에 영향을 주는 표준 항암보조치료 중 어느 것을 선택할 것인가를 결정하는데 판단의 근거가 되는 마커에 관한 것으로서, 보다 구체적으로는 CO5(complement component C5), CO9(complement component C9) 및 F2(prothrombin)의 조합을 포함하며, 위암 환자의 혈액, 혈청 또는 혈장 내에서상기 CO5, C09 및 F2의 발현정도를 측정함으로써 위암의 예후의 판정이 가능한, 위암 예후 판정용 마커를 제공한다.